Study to Evaluate the Safety and Efficacy TPI ASM8 in Subjects With Asthma - Full Text View

Sponsor:	Topigen Pharmaceuticals
Collaborator:	i3 Research
Information provided by (Responsible Party):	Topigen Pharmaceuticals
ClinicalTrials.gov Identifier:	NCT00550797

Purpose

The researchers propose to study the airways of asthmatics given TPI ASM8 for 14 days, and examine the protective effects on allergen-induced bronchoconstriction, hyperresponsiveness and airway inflammation.

Condition	Intervention	Phase
Allergic Asthma	Biological: TPI ASM8 Biological: placebo	Phase 2

Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Crossover Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment
Official Title:	A Multi-center, Double-blind, Randomized, Placebo-controlled, Crossover Study to Evaluate the Safety and Efficacy of 14-day Inhaled TPI ASM8 in Subjects With Asthma

Resource links provided by NLM:

MedlinePlus related topics: Asthma

U.S. FDA Resources

Further study details as provided by Topigen Pharmaceuticals:

Primary Outcome Measures:

Safety and allergen-induced maximum decrease in FEV1 for Late Asthmatic Response [ Time Frame: Safety (Trial duration) + LAR (Day 14) ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:

Exploratory Endpoints only: EAR on Day 14, AMP-induced airway hyperresponsiveness on Day 10,eNO on Day 14, PK/PD in sputum and plasma [ Time Frame: study duration ] [ Designated as safety issue: Yes ]

Enrollment:	18
Study Start Date:	January 2008
Study Completion Date:	October 2008
Primary Completion Date:	July 2008 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: No.1 ASM8 (oligonucleotide) TPI ASM8 1mg/mL in phosphate buffered saline (PBS) solution; 1 mg will be administered daily (morning) by inhalation	Biological: TPI ASM8 Administered with the I-Neb device from Respironics once daily by inhalation over 2 treatment periods of 14 days each
Placebo Comparator: Phosphate Buffer solution Placebo solution (PBS) will be administered daily in the form of 1 mL of PBS (phosphate buffered saline) by inhalation	Biological: placebo Administered with the I-Neb device from Respironics once daily by inhalation over 2 treatment periods of 14 days each

Detailed Description:

Early and late asthmatic responses were attenuated by ASM8 and by placebo solution.Methacohline challenge was not affected by study medication. Other parameters were unchanged.

Eligibility

Ages Eligible for Study:	18 Years to 65 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Men and women 18 to 65 years of age
Intermittent mild to moderate allergic asthma as defined by ATS/ERS criteria
History of episodic wheeze and shortness of breath

Exclusion Criteria:

Significant acute or chronic medical, neurologic, cardiovascular or psychiatric illness, asthma exacerbation or respiratory infection in the preceding 6 weeks
Use of oral/injectable corticosteroids within the last 60 days or currently on any anti-asthmatic drugs, immunosuppressives, nonsteroidal anti-inflammatory drugs or anticoagulants

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00550797

Locations

United Kingdom
King's College inLondon
London, United Kingdom, SE1 9RT

Sponsors and Collaborators

Topigen Pharmaceuticals

i3 Research

Investigators

Principal Investigator:	Brian O'Connor, MD	Kings College Hospital, London, United Kingdom
Study Director:	Rene Pageau, M.Sc.Pharm	Topigen Pharmaceuticals, Montreal, Quebec/Canada
Principal Investigator:	Pierluigi Paggiaro, Prof	University of Pisa, Pisa, Italy
Principal Investigator:	Dave Singh, MD	Evaluation Unit, Manchester, UK
Principal Investigator:	Peter J. Sterk, MD	University of Amsterdam, Amsterdam, The Netherlands
Principal Investigator:	Piero Maestrelli, Prof.	University of Padova, Padova, Italy

More Information

No publications provided

Responsible Party:	Topigen Pharmaceuticals
ClinicalTrials.gov Identifier:	NCT00550797 History of Changes
Other Study ID Numbers:	TPI ASM8-205
Study First Received:	October 26, 2007
Last Updated:	February 1, 2012
Health Authority:	United States: Food and Drug Administration United Kingdom: Medicines and Healthcare Products Regulatory Agency France: Afssaps - French Health Products Safety Agency Netherlands: Medicines Evaluation Board (MEB) Italy: Ministry of Health

Keywords provided by Topigen Pharmaceuticals:

Steroid-naive, non-smokers
Mild to moderate allergic asthmatic adults

Additional relevant MeSH terms:

Asthma
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases

Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases

ClinicalTrials.gov processed this record on May 22, 2012